1. Bertrand Coiffier Professor, Department of Haematology, Hospices Civils de Lyon and University Claude Bernard, Lyon, France Prior posts at the Edouard-Herriot Hospital and the Centre Hospitalier Lyon-Sud, Lyon, France Member of the American Society of Hematology, the American Society of Clinical Oncology, the International Society for Medical Oncology, and the European Haematology Association Founding member of the Group d’Etude des Lymphomes de l’Adulte (GELA) and the European Task Force on Lymphoma Université Claude Bernard

2. Chair’s opening Challenges for the treatment of Non-Hodgkin’s lymphoma and chronic lymphocytic leukaemia Bertrand Coiffier Centre Hospitalier Lyon-Sud Lyon, France

3. Friday 8 February 2008 Agenda 11.30Chair’s opening Bertrand Coiffier 11.35 Rituximab in aggressive NHL: why combination therapy should not be delayed Bertrand Coiffier 12.05 Indolent NHL: a survival benefit with rituximab-based therapy Christian Buske 12.35Discussion 12.50Lunch 14.30Meet the Expert sessions 15.30Coffee break 16.00 Maintenance treatment in follicular lymphoma: indications and considerations Marinus van Oers 16.30 CLL treatment today and tomorrow: the role of rituximab Stephen Mulligan 16.55 Management of relapsed CLL: why rituximab? John Gribben 17.15 Discussion and close

4. NHL and CLL: introduction NHL and CLL are cancers that affect B- and T-lymphocytes NHLs are a heterogenous group of diseases with two major subtypes –indolent –aggressive CLL is also heterogenous but in the majority of patients behaves like an indolent lymphoma with slow progression

5. NHL: what are the challenges that we face in the next decade? Establishing optimal therapeutic combinations in the treatment of advanced stage follicular lymphoma Defining the role of maintenance therapy in follicular lymphoma Identifying optimal treatment strategies for young patients with high-risk DLBCL Prognostic factors in DLBCL: is clinical risk-adapted therapy a viable option? Optimal management of medically non-fit patients with follicular lymphoma DLBCL = Diffuse Large B Cell Lymphoma

6. CLL: what are the challenges that we face in the next decade? Determining the therapeutic options for patients with fludarabine-refractory CLL Identifying optimal management strategies for elderly patients with CLL and renal impairment Determining when CLL treatment should be initiated Establishing whether novel prognostic factors should be integrated into treatment decisions for CLL Optimal management of patients with relapsed CLL